

Milford Australian Absolute Growth Fund - W Class

December 2021



Portfolio Managers



William Curtayne
Portfolio Manager



Wayne Gentle
Portfolio Manager

December ended up being a relatively strong month for the equity market as fears surrounding the Omicron variant receded with more evidence emerging of less severe symptoms and lower hospitalisation rates. The Australian Absolute Growth Fund ended the month up 1.8%, behind the ASX 200 Index which was up 2.8%.


Our best performer over the month was biotech Neuren Pharmaceuticals, which stormed 109.4% after announcing positive phase 3 trial results for its drug Trofinetide. Trofinetide looks likely to be the first FDA approved treatment for Rett Syndrome. We continued to build our position in Neuren after the results given the commercialisation opportunity is significantly de-risked.

One of our worst performers was Woolworths after delivering a downgrade to expectations reflecting higher costs of doing business, particularly in their online channel as states locked down. In other notable portfolio news CSL also announced a deal to acquire Swiss business Vifor pharmaceutical, which is focused on treatments for renal dysfunction and iron deficiency. We participated in its discounted equity raise given the compelling value on offer.

We are now in a situation where monetary policy will almost certainly be tightening, with the Fed flagging faster deceleration of asset purchases, earlier rate rises and a potential for quantitative tightening. We remain mindful this tightening environment is likely to slow growth and drive volatility for markets. We also expect underlying sector rotations to remain a feature.

Given this backdrop the Fund remains relatively cautiously positioned for volatility, with a good mix of quality holdings, those with attractive valuations and some beneficiaries to a rising rate environment. We are also carrying a robust cash level coupled with some derivative protection, which should help cushion any downside volatility we see in the market. Through this we continue to expect stock picking opportunities will appear that we will capitalise on as more attractive risk/reward opportunities present themselves.

Investment Performance to December 2021*



* Cumulative performance since inception, after all fees and expenses, and assumes reinvestment of distributions.

Key Fund Facts

Objective

Absolute returns with an annualised return of 5% above the RBA Cash Rate while seeking to preserve investor capital over rolling three-year periods.

Description

A diversified portfolio of predominantly Australian equities, complemented by selective exposure to international equities and cash. May use derivatives and foreign currency hedging.

Benchmark	RBA Cash Rate + 5% p.a.
APIR	ETL8155AU
Redemption Price as at 31 Dec	\$1.2938
NAV as at 31 Dec	\$143.4 Million
Inception Date	October 2017
Minimum Investment	\$5,000,000
Recommended Investment Timeframe	5 years +
Buy-sell Spread	+/-0.20%
Entry/Exit Fee	Nil
Management Fee	0.90%
Performance Fee	15.35% p.a. of returns above the benchmark subject to achieving the high watermark.
Fund Pricing	Daily
Distribution Frequency	Biannual

Investment Performance to December 2021*

	1 Month	6 Months	1 year	3 years (p.a.)	5 years (p.a.)	Since inception (p.a.)**
Milford Australian Absolute Growth Fund	1.78%	4.52%	18.15%	15.07%	-	12.27%
Benchmark	0.42%	2.53%	5.09%	5.53%	-	5.82%
Over/Underperformance	1.36%	1.99%	13.06%	9.54%	-	6.45%
S&P/ASX 200 (TR) Index	2.75%	3.84%	17.23%	13.62%	-	10.60%
Over/Underperformance	-0.97%	0.68%	0.92%	1.45%	-	1.67%

Past performance is not a reliable indicator of future performance.

* Net performance figures are shown after all fees and expenses, and assumes reinvestment of distributions.

** Inception date of the Fund is 02 October 2017.

Top Security Holdings

Holdings	% of Fund
CSL	7.32%
NAB	6.78%
Telstra	4.65%
Sydney Airport	4.46%
BHP	3.77%
CBA	3.51%
Woolworths	3.49%
Coles	3.09%
Metcash	3.04%
Santos	2.99%


Current Asset Allocation

	Actual	Typical Range	Maximum Range
Australian Equities*	72.97%	75-85%	0-100%
International Equities	1.28%	0-10%	0-30%
Cash and Other #	25.75%	0-10%	0-100%

* Includes New Zealand Equities

Effective Cash reported above is adjusted to reflect the Fund's notional positions.

Sector Allocation



Ratings



Awards



Fund Changes

There have been no material changes to the Fund's risk profile or strategy since the last monthly report. There have been no changes to the key service providers or individuals playing a key role in investment since the last monthly report.



Disclaimer: Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the responsible Entity for the Milford Australian Absolute Growth Fund. Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This Monthly Fact Sheet has been prepared by Milford Australia Pty Ltd. as the Investment Manager, to provide you with general information only. In preparing this Monthly Fact Sheet, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Milford Australia Pty Ltd., Equity Trustees nor any of their related parties, employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance is not a reliable indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product.

Milford Australian Absolute Growth Fund's Target Market Determination is available at <https://milfordasset.com.au/forms-documents.au>. The Target Market Determination is a document describing who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.

ZENITH DISCLAIMER: The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned June/2021) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>

The Zenith Fund Awards were issued October 2020 by Zenith Investment Partners (ABN 27 130 132 672, AFSL 226872) and are determined using proprietary methodologies. The Fund Awards are solely statements of opinion and do not represent recommendations to purchase, hold or sell any securities or make any other investment decisions. To the extent that the Fund Awards constitutes advice, it is General Advice for Wholesale clients only without taking into consideration the objectives, financial situation or needs of any specific person. Investors should seek their own independent financial advice before making any investment decision and should consider the appropriateness of any advice. Investors should obtain a copy of and consider any relevant PDS or offer document before making any investment decisions. Past performance is not an indication of future performance. Fund Awards are current for 12 months from the date awarded and are subject to change at any time. Fund Awards for previous years are referenced for historical purposes only.

LONSEC DISCLAIMER: The rating issued 08/2020 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2020 Lonsec. All rights reserved.